Indonesia’s food and drug authority is BPOM (Badan Pengawas Obat dan Makanan). Like most countries, BPOM approves specific finished drug products for the Indonesian market — peptides as “research chemicals” are generally NOT registered products, which is the crux of the grey area. The narcotics law (UU No. 35/2009) covers narcotics and psychotropics; most research peptides are not classified under it, but the legal status of specific compounds can change.

A small number of peptide-based drugs ARE registered in Indonesia — most notably GLP-1 products for diabetes/obesity (semaglutide/Ozempic-type products are available by prescription at pharmacies). Unregistered peptides sold as “research chemicals” (BPC-157, GHK-Cu, CJC-1295, etc.) exist in a grey zone: not approved for medical use, not clearly controlled, but not legal to import for personal use either. This mirrors the situation in most of Southeast Asia.

Expat community reports (Reddit, Facebook groups) describe packages of lyophilized peptides being held or confiscated by Indonesian customs (bea cukai). Risk depends on declared contents, package value, and inspection luck. There is no reliable public guidance that makes peptide importation “safe” — treat international ordering as a genuine risk. Domestic sourcing within Bali/Indonesia avoids customs exposure but shifts risk to source reliability.

If you are a Bali expat considering peptides: (1) clinic-administered therapy for approved indications is the legally safest route; (2) importing unregistered vials carries customs risk — do your own research and accept it consciously; (3) BPOM status can change, so re-check current rules before ordering; (4) this is NOT legal advice — for certainty, consult an Indonesian lawyer or expat legal service.